Before COVID-19, most kidney- and heart-transplant recipients got their weekly or monthly blood tests at the hospital or a local blood-draw center. When COVID-19 touched down, however, hospitals became places where exposure to the coronavirus was higher.
Patients who are on immunosuppression—such as transplant recipients—are likely to be at a higher risk of severe infection and associated complications of COVID-19.1 Therefore, it is critical that transplant recipients have routine access to their transplant-lab testing in environments that limit their exposure to the coronavirus.
How do you solve such a dilemma?
Since March 2020, over 5,000 transplant recipients have turned to RemoTraC.
Learn more about RemoTraC, here.